Class of olefin metathesis catalysts, methods of preparation, and processes for the use thereof
申请人:ExxonMobil Chemical Patents Inc.
公开号:US08227371B2
公开(公告)日:2012-07-24
This invention relates to a metathesis catalyst comprising (i) a Group 8 metal hydride-dihydrogen complex represented by the formula:
wherein M is a Group 8 metal; X is an anionic ligand; and L1 and L2 are neutral donor ligands; and (ii) a ligand exchange agent represented by the formula J-Y, wherein J is selected from the group consisting of hydrogen, a C1 to C30 hydrocarbyl, and a C1 to C30 substituted hydrocarbyl; and Y is selected from the group consisting of halides, alkoxides, aryloxides, and alkyl sulfonates.
METHOD FOR SYNTHESIZING CYCLOHEXYL-SUBSTITUTED PHOSPHINES
申请人:Tishkov Alexander
公开号:US20100137643A1
公开(公告)日:2010-06-03
The present invention relates to a process for preparing cyclohexyl-substituted phosphines. The invention further relates to a process for preparing cyclohexyl-substituted phosphine oxides which can be used as intermediates in the preparation of cyclohexyl-substituted phosphines.
[EN] NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE<br/>[FR] NOUVEAUX LACTAMES FONCTIONNALISÉS COMME MODULATEURS DU RÉCEPTEUR 7 DE LA 5-HYDROXYTRYPTAMINE, ET PROCÉDÉ POUR LEUR UTILISATION
申请人:UNIV TEMPLE
公开号:WO2021097116A1
公开(公告)日:2021-05-20
Described herein are new, selective modulators of the 5 -HT7 receptor. These selective compounds can be useful for the treatment of CNS and non-CNS indications. Compounds described herein can be selective in targeting 5-HT7 receptors as compared to other receptors and/or by selective targeting 5-HT7 receptors expressed in certain tissues or organs, thereby effective selectivity through a particular partitioning profile of the 5- HT7 modulator.
The Phosphonium Ion [Cy
<sub>3</sub>
PCHCl
<sub>2</sub>
]
<sup>+</sup>
: Synthesis and Properties
作者:Nils Spang、Matthias Müller、Magnus R. Buchner
DOI:10.1002/ejic.201800532
日期:2018.8.31
cation [Cy3PCHCl2]+ (3) has been evaluated by using in situ 31P NMR spectroscopy and mass spectrometry. The synthesis is only successful if CCl4/CHCl3 mixtures are used. A mechanism for the varying reactivity in different solvents is given as well as a mechanism for the observed equilibrium between ions [Cy3PCHCl2]+ and [Cy3PCH2Cl]+ (12). Through the anticipated hydrogen bonding interaction between [Cy3PCHCl2]+
Upon activation with C2Cl6 known latent Ru metathesis catalyst LatMet (13) exhibited activity in RCM and in ROMP of DCPD. A by-product of such activation, an aryloxybenzylidene ruthenium(III) complex 17 have been independently synthesised by reacting 13 with C2Cl6. This unique complex was characterised by spectroscopic and electrochemical methods, and by X-ray crystallography. To the best to our knowledge